See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the ...

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

COMPASS Pathways (NASDAQ:CMPS) used an investor update webinar to highlight positive results from its Phase III COMP005 and ...

Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Feb 17 () - ‌Drug ‌developer Compass ​Pathways said on ‌Tuesday ⁠its ⁠psilocybin-based ​depression ​therapy ​met ‌the main goal ‌in ​a ​late-stage ​study. (Reporting ‌by Sahil ​Pandey ​in ​Bengaluru; ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.